Changes in expression level of various chemokines in mobilized granulocytes
| Accession number . | Gene symbol . | Protein encoded . | mRNA, fold change . |
|---|---|---|---|
| NM_001511 | CXCL1 | Chemokine (C-X-C motif) ligand 1; GROβ (melanoma growth stimulating activity, alpha) | −3.20 |
| NM_001001437 | CCL3L3 | Chemokine (C-C motif) ligand 3-like 3 | −5.98 |
| NM_002983 | CCL3 | Chemokine (C-C motif) ligand 3; MIP-1α | −6.35 |
| NM_002985 | CCL5 | Chemokine (C-C motif) ligand 5; RANTES | −7.71 |
| NM_002619 | CXCL4 | Chemokine (C-X-C motif) ligand 4; PF4 | −11.0 |
| NM_005064 | CCL23 | Chemokine (C-C motif) ligand 23; MPIF-1 | −15.06 |
| NM_002984 | CCL4 | Chemokine (C-C motif) ligand 4; MIP-1β | −15.45 |
| NM_002704 | CXCL7 | Chemokine (C-X-C motif) ligand 7; pro-platelet basic protein | −16.30 |
| NM_002001 | CXCL8 | Chemokine (C-X-C motif) ligand 8; interleukin-8 | −35.22 |
| Accession number . | Gene symbol . | Protein encoded . | mRNA, fold change . |
|---|---|---|---|
| NM_001511 | CXCL1 | Chemokine (C-X-C motif) ligand 1; GROβ (melanoma growth stimulating activity, alpha) | −3.20 |
| NM_001001437 | CCL3L3 | Chemokine (C-C motif) ligand 3-like 3 | −5.98 |
| NM_002983 | CCL3 | Chemokine (C-C motif) ligand 3; MIP-1α | −6.35 |
| NM_002985 | CCL5 | Chemokine (C-C motif) ligand 5; RANTES | −7.71 |
| NM_002619 | CXCL4 | Chemokine (C-X-C motif) ligand 4; PF4 | −11.0 |
| NM_005064 | CCL23 | Chemokine (C-C motif) ligand 23; MPIF-1 | −15.06 |
| NM_002984 | CCL4 | Chemokine (C-C motif) ligand 4; MIP-1β | −15.45 |
| NM_002704 | CXCL7 | Chemokine (C-X-C motif) ligand 7; pro-platelet basic protein | −16.30 |
| NM_002001 | CXCL8 | Chemokine (C-X-C motif) ligand 8; interleukin-8 | −35.22 |
Granulocytes were isolated from blood of donors before and after treatment with G-CSF/dexa. Changes in gene expression were evaluated by Agilent Whole Human Oligomicroarray, and shown in order of magnitude of changes in transcription. Significantly regulated genes were selected with Rosetta Resolver. Genes with a fold change of 3 or more together with a P-value cutoff of .01 or less (1-way ANOVA test with the Benjamini-Hochberg false-discovery rate correction) were considered significantly different.